Regulator investigates Ozempic suicidal ideation link

Novo Nordisk’s diabetes medication, Ozempic (semaglutide) and weight-loss treatment Saxenda (liraglutide) are being investigated, following reports they may be associated with suicidal ideation  The European Medicines Agency (EMA) is looking into adverse events flagged by the Icelandic Medicines Agency, relating to three cases of patients reporting suicidal ideation, Reuters reports.   The investigation is set

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Overstepping the boundaries
Next Illicit drug role like ‘my involvement with customers,’ says jailed pharmacist